What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.8% in the afternoon session after a court ruling in ...

Regeneron Pharmaceuticals expects to record an acquired in-process research-and-development charge of approximately $83 million in the third quarter.

Compared to the aggregate P/E ratio of the 31.18 in the Biotechnology industry, Regeneron Pharmaceuticals Inc. has a lower ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the best biotech stocks to buy. On September 17, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed the findings of its Phase 2 COURAGE ...

Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous ...

Regeneron’s monoclonal antibody trevogrumab, with or without the anti-activin A antibody garetosmab, appears to preserve lean ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial ...

Inmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most promising biotech stocks to buy according to hedge funds.

As academic researchers experience a worsening funding crunch and pharma companies are increasingly hungry for large, ...

Regeneron's Evkeeza gains FDA approval for treating young children with homozygous familial hypercholesterolemia, addressing ...

Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIf approved, Dupixent would be the first ...